Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.640
+0.270 (11.39%)
Aug 1, 2025, 4:00 PM - Market closed
Instructure Holdings Employees
As of December 31, 2024, Cardiff Oncology had 33 total employees, including 32 full-time and 1 part-time employees. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
$16,515
Profits / Employee
-$1,546,758
Market Cap
175.63M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 33 | 1 | 3.13% |
Dec 31, 2023 | 32 | 6 | 23.08% |
Dec 31, 2022 | 26 | 3 | 13.04% |
Dec 31, 2021 | 23 | 11 | 91.67% |
Dec 31, 2020 | 12 | -2 | -14.29% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CRDF News
- 3 days ago - Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - Benzinga
- 3 days ago - Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
- 4 days ago - Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) - GlobeNewsWire
- 5 weeks ago - Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha
- 6 weeks ago - Cardiff Oncology Names Roger Sidhu as Medical Chief - Market Watch
- 6 weeks ago - Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC - GlobeNewsWire
- 2 months ago - Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 - GlobeNewsWire
- 2 months ago - Cardiff Oncology: Buying The First-Line Onvansertib Strategy - Seeking Alpha